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HypertensionTETSUYA YAMAMOTO, TORU IKEGAMI, YUJI ISHIKAWA, AND SATORU KIKUCHI, FOR THE OPC-1085EL
1 & 2 STUDY GROUPS PURPOSE: To assess the intraocular pressure (IOP)-
lowering effects and safety of a carteolol/latanoprost fixed
combination drug (OPC-1085EL) vs latanoprost (Study
1) and carteolol (Study 2) in patients with primary
open-angle glaucoma (POAG) or ocular hypertension
(OH).
 DESIGN: Multicenter, randomized, evaluator-masked
(Study 1)/double-masked (Study 2), parallel-group
studies.
 METHODS: SETTING: Twenty-eight clinical sites (Study
1) and 19 clinical sites (Study 2) in Japan. STUDY POPULA-
TION: Outpatients with bilateral POAG or OH whose
predose IOP was 18 to<35 mmHg in the study eye after
4 weeks’ treatment with latanoprost (Study 1) or carteolol
(Study 2) (defined as baseline). INTERVENTION: In Study 1,
237 patients applied OPC-1085EL (n[ 118) or latano-
prost (n [ 119) for 8 weeks. In Study 2, 193 patients
applied OPC-1085EL (n [ 78), carteolol (n [ 78), or
carteolol/latanoprost concomitant therapy (n [ 37) for
8 weeks. MAIN OUTCOME MEASURE: Adjusted mean IOP
reduction at predose from baseline to week 8.
 RESULTS: In Study 1, the adjusted mean IOP reduc-
tions (95% confidence interval [CI]) were 2.9 (2.5-3.3)
mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL
and latanoprost groups, respectively (P < .0001). In
Study 2, the adjusted mean IOP reductions (95% CI)
were 3.5 (3.1-3.9) mm Hg and 1.6 (1.2-2.0) mm Hg in
the OPC-1085EL and carteolol groups, respectively (P
< .0001). All adverse drug reactions of OPC-1085EL
observed in both studies were mild in severity and only
1 patient in each study discontinued because of an adverse
drug reaction.
 CONCLUSIONS: OPC-1085EL is superior to latano-
prost or carteolol alone in terms of lowering IOP, andupplemental Material available at AJO.com.
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G
LAUCOMA IS THE SECOND-LEADING CAUSE OF
blindness worldwide.1 Open-angle glaucoma
(OAG) is the commonest type of glaucoma, and
it is estimated that it will affect around 59 million patients
in 2020.2 Elevated intraocular pressure (IOP) is the primary
risk factor for the onset and progression of glaucoma. IOP-
lowering treatment is the only therapeutic approach with
clear evidence for preventing glaucoma and suppressing
its progression.1,3
Patients with glaucoma are often treated with beta
blockers or prostaglandin (PG) analogues. Treatment is
initiated as monotherapy in the majority of the patients,
but poor efficacy or intolerable adverse drug reactions
(ADRs) may lead to a change inmedication or the addition
of a drug with a different mechanism of action.1,4 However,
concomitant therapies may be inconvenient for patients,
fostering poor adherence to treatment. A fixed-
combination drug has advantages over concomitant appli-
cation of single-agent ophthalmic drugs. It can reduce the
number of drugs and the frequency of the applications and
may improve treatment adherence.5,6 Less-frequent appli-
cation also reduces exposure to potentially harmful preser-
vatives in ophthalmic drugs.6,7
Carteolol hydrochloride is a nonselective beta blocker
with intrinsic sympathomimetic activity that reduces IOP
with twice-daily (BID) application. It increases blood
flow in the fundus8 and has less impact on the cardiovascu-
lar system9 and respiratory function10 than timolol male-
ate. It is also less likely to cause eye irritation11 and has
less impact on blood lipid profiles.12 Once-daily (QD)
carteolol (carteolol LA), which was formulated by adding
alginic acid to prolong the IOP-lowering effects, is avail-
able in many countries.13–16 Latanoprost, a PGF2a
analogue, is widely used for the treatment of glaucoma
owing to its strong IOP-reducing activity and good
safety profile, and was recently shown to have a visual35BLISHED BY ELSEVIER INC.
field-preserving effect in a placebo-controlled trial.17
Adding carteolol to latanoprost increases the IOP-lowering
effect.18 A fixed-combination treatment of carteolol and
a PG analogue represents a new therapeutic option capable
of improving convenience and adherence to concomitant
therapy. OPC-1085EL is a newly developed ophthalmic
solution containing carteolol hydrochloride 2% and
latanoprost 0.005%. Because OPC-1085EL contains the
same concentration of alginic acid as carteolol LA and
the same dose of latanoprost as administered QD, the
daily dose of each active ingredient is formulated to be
the same as concomitant therapy with carteolol LA and
latanoprost. It does not contain benzalkonium chloride,
meaning that OPC-1085EL should be safer for the corneal
epithelium.
The objectives of the 2 studies reported in this article
were to assess the IOP-lowering effects and safety of
OPC-1085EL compared with monotherapy with latano-
prost (Study 1) or with carteolol LA (Study 2) in patients
with primary OAG (POAG; including normal tension
glaucoma [NTG]) or ocular hypertension (OH). In Study
2, OPC-1085EL was also compared with carteolol/latano-
prost concomitant therapy.METHODS
THESE WERE 2 PHASE 3, MULTICENTER, ACTIVE-
controlled, randomized, evaluator-masked (Study 1)/dou-
ble-masked (Study 2), parallel-group comparative studies
in patients with POAG (including NTG) or OH. The
studies were conducted in 28 clinical sites from April 28,
2014 to March 20, 2015 (Study 1) and in 19 clinical sites
from April 27, 2014 to January 21, 2015 (Study 2) in
Japan. Both studies were performed according to the tenets
of the Helsinki Declaration and in compliance with the
International Conference on Harmonization Good Clin-
ical Practice and Japanese regulations. Prior to enrollment,
written informed consent was obtained from the patients.
The informed consent document covered all prospective
treatments and study measures; it was not necessary to
obtain retrospective consent for any procedures. The
informed consent documents and the study protocols
were reviewed and approved by the institutional review
board of each study site. Both studies were registered on
ClinicalTrials.gov (Study 1: NCT02105272; Study 2:
NCT02105285). The list of investigators and participating
sites is shown in the Supplemental Materials (available at
AJO.com).
 PATIENTS: Outpatients aged 20-80 years with bilateral
POAG or OH and with a predose IOP of 18 to <35 mm
Hg in the unilateral eye and IOP <35 mm Hg in the
contralateral eye at the end of the screening period were
eligible. Patients with the following were excluded: (1)36 AMERICAN JOURNAL OFbest-corrected visual acuity (decimal unit) <_0.2; (2) hyper-
sensitivity to any ingredients in carteolol or latanoprost
ophthalmic drug; (3) nonresponder to beta blockers (Study
1) or PG analogues (Study 2); (4) presence or history of
ocular disease, such as progressive retinal disease, severe
dry eye, angle closure, ocular infection, endophthalmitis,
acute ocular inflammation, corneal foreign body, ocular
trauma, herpes keratitis, or corneal ulcer; (5) cataract or
intraocular surgery, aphakia, or intraocular lens; and (6)
poorly controlled cardiac failure, sinus bradycardia, atrio-
ventricular block, bronchial asthma, severe chronic
obstructive pulmonary disease, or poorly controlled dia-
betes mellitus.
 STUDY TREATMENTS: The study drugs used during the
evaluation period were carteolol hydrochloride 2%/latano-
prost 0.005% fixed-combination ophthalmic solution
(OPC-1085EL) and latanoprost 0.005% (Xalatan; Pfizer
Japan Inc, Tokyo, Japan) in Study 1, and OPC-1085EL
and carteolol hydrochloride 2% long-acting formulation
(Mikelan LA 2%; Otsuka Pharmaceutical Co, Ltd, Tokyo,
Japan) and latanoprost 0.005% in Study 2. During the
screening period, the run-in drugs (latanoprost in Study
1; carteolol in Study 2) were applied QD in the morning
from the day after the screening period started to the last
day of the screening period. During the evaluation periods,
the study drugs were applied QD in the morning until the
end of the last day of the evaluation period from the day af-
ter the last day of the screening period.
The study designs are shown in Figure 1. In Study 1, after
application of latanoprost during a 4-week screening
period, eligible patients were randomized to either OPC-
1085EL (OPC group) or latanoprost (LAT group) in a
1:1 fashion and were treated for 8 weeks under evaluator-
masked conditions. Patients in the LAT group received
latanoprost for a total of 12 weeks from the start of the
screening period until the end of the evaluation period.
In Study 2, the patients applied carteolol during the
screening period and were then randomized to OPC-
1085EL (OPC group), carteolol (CAR group), or carteo-
lol/latanoprost concomitant therapy (CAR-LAT group)
in a 2:2:1 fashion and were treated for 8 weeks under
double-masked conditions for OPC and CAR or under
evaluator-masked conditions for CAR-LAT. Patients in
the CAR and CAR-LAT groups received CAR for a total
of 12 weeks from the start of the screening period until the
end of the evaluation period.
During the screening and evaluation periods, the study
drug was applied in both eyes, 1 drop, QD, between 9
AM and 11 AM. In the CAR-LAT group in Study 2,
carteolol was applied 10 minutes after latanoprost. Patients
were instructed to conduct nasolacrimal occlusion to both
eyes for 1-5 minutes after application. The study drug was
applied >_10 minutes after any concomitant ophthalmic
drug. Concomitant use of any IOP-lowering agents, sys-
temic corticosteroids, topical corticosteroids applied toNOVEMBER 2016OPHTHALMOLOGY
FIGURE 1. Study designs. Eligible patients were randomized to either OPC-1085EL or latanoprost in a 1:1 fashion in Study 1 and
OPC-1085EL, carteolol, or carteolol/latanoprost concomitant therapy in a 2:2:1 fashion in Study 2. R, randomization.the eyelids or eyes, and any other drugs that may affect IOP
were prohibited. Topical corticosteroids applied elsewhere
were permitted. Other prohibited concomitant therapies
included ophthalmic surgery and treatment (eg, laser treat-
ment, contact lens).
IOP was measured at the end of the screening period
(baseline) and in week 8 of the evaluation period at the
following times at both visits: predose (9 AM to 11 AM),
2 hours after dosing, and 8 hours after dosing. IOP was
also measured at predose at week 4 after the start of treat-
ment in the evaluation period. The IOP measurement at
8 hours was performed only for patients who consented to
this procedure. IOP was measured once at each time point
in a sitting position using the Goldmann applanation
tonometer after topical anesthesia.
Central randomization was performed to assign patients
to each group with a dynamic allocation method that
included stratification by center and baseline IOP at
predose (18 to <21 mm Hg; 21 to <24 mm Hg; and
>_24 mm Hg). The study drugs were coded based on the
randomization list prepared by the controller.
Commercially available latanoprost (Xalatan) was used
to ensure its quality.Measures were taken tomaintainmask-
ing, including implementing procedures for packaging, allo-
cation, supply, and collection of the study drugs; handling of
patients; and topical application at the study sites.
 EFFICACY PARAMETERS: The study eye was defined as
the eye with the highest IOP at predose at the end of the
screening period, or the right eye if the IOP values of
both eyes were equal. The primary endpoint was the
adjusted mean IOP reduction at predose from baseline to
week 8. Secondary efficacy endpoints included the mean
IOP, adjusted mean IOP reduction at each time point at
weeks 4 and 8, and the proportions of patients achieving
the target IOPs (<_18, <_16, or <_14 mm Hg) or the target
IOP reductions (>_2, >_4, or >_6 mm Hg) at week 8.VOL. 171 PHASE 3 TRIALS OF CARTEOLOL/LAT SAFETY PARAMETERS: Safety variables included adverse
events (AEs), physical examination findings, subjective
ocular symptoms, comfort in the use of the study drug, vital
signs (blood pressure, pulse rate), visual acuity, slit-lamp
microscopy, fundus examinations, and clinical laboratory
tests. AEs were coded using theMedical Dictionary for Reg-
ulatory Activities (MedDRA), version 17.0., and were clas-
sified as mild (discomfort, but no disruption of normal daily
activity), moderate (sufficient discomfort to reduce or affect
daily activity), and severe (unable to work or perform
normal daily activity). The comfort in the use of the study
drug was rated on a 4-point scale by clinical interview: 0:
‘‘No problems with application at all’’; 1: ‘‘Some trouble
with application, but no problems’’; 2: ‘‘Trouble with appli-
cation, but bearable’’; and 3: ‘‘Unbearable trouble with
application’’. ADRs were defined as AEs that occurred dur-
ing the evaluation period for which a causal relationship
with the study drug could not be ruled out.
 STATISTICAL ANALYSIS: To determine the sample size
in both studies, the difference in IOP reduction between
the OPC and LAT groups was assumed to be 1.5 mm
Hg18–21 and that between the OPC and CAR groups to
be 2 mm Hg.22–24 The standard deviation for IOP
reduction in the 2 studies was estimated to be 3.2 mm
Hg. Based on these assumptions, 97 patients per group for
Study 1 and 55 per group for Study 2 were required to
detect a difference with a 2-sided significance level of .05
and a power of 90%.Moreover, allowing for exclusions, dis-
continuations, and dropouts, 220 patients (with a ratio for
OPC:LAT of 1:1) were required for Study 1 and 175 pa-
tients (with a ratio for OPC:CAR:CAR-LAT of 2:2:1;
70, 70, and 35 patients, respectively) for Study 2.
The efficacy population included all randomized patients
who received any dose of the study drug, had an IOP mea-
surement at the end of screening, and had at least 1 postba-
seline IOP measurement (full analysis set, FAS).37ANOPROST FIXED COMBINATION
FIGURE 2. Flow charts showing patient dispositions in Study 1 and Study 2. OPC[ OPC-1085EL; LAT[ latanoprost; CAR[
carteolol; CAR-LAT[ carteolol/latanoprost concomitant therapy.Analysis of covariance was performed to compare the
mean IOP and the mean IOP reduction between OPC
and LAT (Study 1) and between OPC and CAR (Study
2), with treatment group as a fixed factor and baseline
IOP as a covariate. These analyses yielded baseline-
adjusted mean changes in IOP. The proportions of patients
achieving the target criteria were compared using logistic
regression models.
The safety population included all patients who received
any dose of the study drug (safety set, SS). The number of
patients with AEs was tabulated for each treatment group.
Missing values in the efficacy analyses were imputed us-
ing the last-observation-carried-forward (LOCF) approach.
Values obtained before topical application of the study drug
were not used for imputation. At each visit, for patients
with poor compliance with the study drug treatment, cate-
gorized as ‘‘No application on the day before the visit,’’ the
data at the visit were used in the analysis. For patients with
poor compliance with the study drug treatment, categorized
as ‘‘Visited the site after application on the day of visit,’’ the
data obtained at ‘‘2 hours after morning application’’ and ‘‘8
hours after morning application’’ at the visit were used in
the analysis, but the data obtained ‘‘predose, before morn-
ing application’’ were excluded.
The SAS software package version 9.2 (SAS Institute
Inc, Cary, North Carolina, USA) was used for all analyses.RESULTS
 STUDY SETTINGSANDPATIENTS: In Study 1, of 238 pa-
tients (119 in each group) who were randomized, 237
received the study drugs (118 and 119 in the OPC and
LAT groups, respectively), and 229 (113 and 116 in the
OPC and LAT groups, respectively) completed
the 8-week treatment (Figure 2). In terms of patient38 AMERICAN JOURNAL OFcharacteristics, there were no obvious differences between
groups except for sex (significance level: 15%; P ¼ .0661)
(Table 1).
In Study 2, 193 patients (78 in each of the OPC and
CAR groups and 37 in the CAR-LAT group) were random-
ized and received the study drugs, and 189 (76 in each of
the OPC and CAR groups and 37 in the CAR-LAT group)
completed the 8-week treatment (Figure 2). There were no
obvious differences in patient characteristics among the 3
groups (Table 1).
 EFFICACY: The mean IOPs at each time point are shown
in Figure 3 and Table 2. The mean baseline IOPs at predose
and at 2 and 8 hours postdose were similar in both groups in
Study 1 and in all 3 groups in Study 2.
Study 1. The adjusted mean IOP reductions (95% con-
fidence interval [CI]) in the OPC and LAT groups at
predose at week 8 (primary endpoint) were 2.9 (2.5, 3.3)
and 1.6 (1.2, 2.0) mm Hg, respectively. The difference in
adjusted mean IOP reduction (95% CI) between the 2
groups (OPC  LAT) was 1.3 (0.7, 1.8) mm Hg
(Table 3). The IOP reduction in the OPC group was
significantly greater than that in the LAT group at all
time points. The reductions in IOP with OPC vs LAT
were also reflected in the subgroup analysis (Table 4).
The proportions of patients achieving the target criteria
(ie, <_18, <_16, and <_14 mm Hg for IOP; or >_2, >_4, and
>_6 mm Hg for IOP reduction) at predose at week 8 were
significantly greater in the OPC group than in the LAT
group (Table 5).
Study 2. The adjusted mean IOP reductions (95% CI)
in the OPC and CAR groups at predose at week 8 (pri-
mary endpoint) were 3.5 (3.1, 3.9) mm Hg and 1.6 (1.2,
2.0) mm Hg, respectively. The difference in adjusted
mean IOP reduction (95% CI) between the 2 groupsNOVEMBER 2016OPHTHALMOLOGY
TABLE 1. Patient Characteristics in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Characteristics
Study 1 Study 2
OPC LAT
P Valuea
OPC CAR
P Valuea
CAR-LAT
N (%) N (%) N (%) N (%) N (%)
Sex
Male 57 (48.3) 43 (36.1) 38 (48.7) 39 (50.0) 16 (43.2)
Female 61 (51.7) 76 (63.9) .0661b 40 (51.3) 39 (50.0) 1.0000b 21 (56.8)
Age
Mean 6 SD, y 59.9 6 11.4 60.8 6 11.5 .5344c 57.9 6 12.1 60.6 6 10.6 .1416c 56.6 6 12.8
Diagnosis
POAG 72 (61.0) 71 (59.7) 39 (50.0) 42 (53.8) 22 (59.5)
NTG 9 (7.6) 7 (5.9) 4 (5.1) 8 (10.3) 4 (10.8)
OH 37 (31.4) 41 (34.5) .7964b 35 (44.9) 28 (35.9) .3414b 11 (29.7)
Baseline IOPd
>_18 to <21 mm Hg 80 (67.8) 78 (65.5) 59 (75.6) 59 (75.6) 28 (75.7)
>_21 to <24 mm Hg 30 (25.4) 34 (28.6) 15 (19.2) 13 (16.7) 6 (16.2)
>_24 mm Hg 8 (6.8) 7 (5.9) .8613b 4 (5.1) 6 (7.7) .8109b 3 (8.1)
Prior medicatione
Present 102 (86.4) 103 (86.6) 61 (78.2) 65 (83.3) 29 (78.4)
Absent 16 (13.6) 16 (13.4) 1.0000b 17 (21.8) 13 (16.7) .5427b 8 (21.6)
CAR¼ carteolol; CAR-LAT¼ carteolol/latanoprost concomitant therapy; IOP¼ intraocular pressure; LAT ¼ latanoprost; NTG¼ normal ten-
sion glaucoma; OH ¼ ocular hypertension; OPC ¼ OPC-1085EL; POAG ¼ primary open-angle glaucoma.
aStudy 1: OPC vs LAT; Study 2: OPC vs CAR.
bFisher exact test.
ct test.
dFor the study eye.
eMedication for POAG, NTG, or OH.
FIGURE 3. Time course of intraocular pressure in Study 1 and Study 2. Values are presented as the mean ± standard deviation (stan-
dard deviations are presented in a 1-sided manner for clarity). Missing values were imputed using the last-observation-carried-forward
method. OPC[ OPC-1085EL; LAT[ latanoprost; CAR[ carteolol; CAR-LAT[ carteolol/latanoprost concomitant therapy.
aNumber of subjects with both nonmissing baseline values and nonmissing values at each time point.
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TABLE 2. Time Course of Intraocular Pressure in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Visit Time Point
Study 1 Study 2
OPC LAT OPC CAR CAR-LAT
N IOP,a mm Hg N IOP,a mm Hg N IOP,a mm Hg N IOP,a mm Hg N IOP,a mm Hg
Baseline Predose 118 20.1 6 2.2 119 20.1 6 1.9 78 19.8 6 1.7 78 19.8 6 2.4 37 19.7 6 2.1
2 hours 118 19.0 6 2.8 119 19.4 6 2.5 78 18.8 6 2.3 78 18.6 6 2.4 37 18.6 6 2.2
8 hours 92 18.4 6 2.5 95 18.5 6 2.3 63 18.5 6 2.7 55 18.0 6 2.4 30 18.3 6 2.4
Week 4 Predose 115 17.3 6 2.7 118 18.6 6 2.6 78 16.7 6 2.2 77 18.1 6 2.8 35 16.9 6 2.6
Week 8 Predose 117 17.2 6 2.7 118 18.4 6 2.7 78 16.3 6 2.1 77 18.2 6 2.7 37 16.6 6 2.6
2 hours 114 17.0 6 2.8 118 18.3 6 3.2 76 15.7 6 2.1 77 17.8 6 3.1 37 16.3 6 3.1
8 hours 88 16.7 6 2.6 92 17.5 6 2.4 62 15.4 6 2.4 54 17.8 6 3.4 30 15.8 6 2.6
CAR ¼ carteolol; CAR-LAT ¼ carteolol/latanoprost concomitant therapy; IOP ¼ intraocular pressure; LAT ¼ latanoprost; OPC ¼ OPC-
1085EL.
Missing values were imputed using the last-observation-carried-forward method.
aMean 6 standard deviation.
TABLE 3. Adjusted Mean Intraocular Pressure Reduction From Baseline in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Study 1 OPC LAT
Differenceb P ValuecVisit Time Point Na IOP Reduction,b mm Hg Na IOP Reduction,b mm Hg
Week 4 Predose 115 2.7 6 0.2 (2.3, 3.1) 118 1.5 6 0.2 (1.1, 1.8) 1.3 6 0.3 (0.7, 1.8) <.0001
Week 8 Predose 117 2.9 6 0.2 (2.5, 3.3) 118 1.6 6 0.2 (1.2, 2.0) 1.3 6 0.3 (0.7, 1.8) <.0001
2 hours 114 2.1 6 0.2 (1.7, 2.4) 118 1.0 6 0.2 (0.6, 1.4) 1.0 6 0.3 (0.5, 1.6) .0003
8 hours 88 1.7 6 0.2 (1.3, 2.1) 92 1.0 6 0.2 (0.6, 1.3) 0.7 6 0.3 (0.2, 1.3) .0108
Study 2 OPC CAR
Differenceb P ValuecVisit Time Point Na IOP Reduction,b mm Hg Na IOP Reduction,b mm Hg
Week 4 Predose 78 3.1 6 0.2 (2.7, 3.6) 77 1.8 6 0.2 (1.3, 2.2) 1.3 6 0.3 (0.7, 2.0) <.0001
Week 8 Predose 78 3.5 6 0.2 (3.1, 3.9) 77 1.6 6 0.2 (1.2, 2.0) 1.9 6 0.3 (1.3, 2.5) <.0001
2 hours 76 2.9 6 0.2 (2.5, 3.3) 77 0.8 6 0.2 (0.4, 1.2) 2.1 6 0.3 (1.6, 2.7) <.0001
8 hours 62 3.0 6 0.3 (2.5, 3.6) 54 0.3 6 0.3 (0.3, 0.8) 2.7 6 0.4 (1.9, 3.5) <.0001
CAR ¼ carteolol; IOP ¼ intraocular pressure; LAT ¼ latanoprost; OPC ¼ OPC-1085EL.
Missing values were imputed using the last-observation-carried-forward method.
aNumber of subjects with both nonmissing baseline values and nonmissing values at each time point.
bMean 6 standard error (95% confidence interval).
cAnalysis of covariance.(OPC  CAR) was 1.9 (1.3, 2.5) mm Hg (Table 3). The
IOP reduction in the OPC group was significantly greater
than that in the CAR group at all time points (P< .0001).
The reductions in IOP with OPC vs CAR were also
reflected in the subgroup analysis (Table 4). The
proportions of patients achieving the target criteria
were significantly greater in the OPC group than in the
CAR group (Table 5). In addition, the IOP reduction at
each time point in the OPC group was similar to that in
the CAR-LAT group (Table 6).
 SAFETY: Study 1. AEs were observed in 30 of 118 pa-
tients (25.4%) in the OPC group and 23 of 119 patients40 AMERICAN JOURNAL OF(19.3%) in the LAT group. ADRs occurred in 8 of 118 pa-
tients (6.8%) in the OPC group and 5 of 119 patients
(4.2%) in the LAT group (Table 7). All ADRs were mild
in severity. ADRs leading to discontinuation of the study
drug were ‘‘visual impairment’’ and ‘‘eye pruritus’’ in 1
patient in the OPC group. Both events were mild in
severity and resolved without treatment. The visual
impairment was considered to be subjective, because the
visual acuity test results showed no decrease. There were
no clinically significant laboratory abnormalities in any
group. Pulse rate and blood pressure in the OPC group
tended to decrease after application, but the magnitude
of these changes was small and not clinically significantNOVEMBER 2016OPHTHALMOLOGY
TABLE 4. Subgroup Analysis of the Mean Intraocular Pressure Reductions at Predose From Baseline to Week 8 in Phase 3 Trials of
Carteolol/Latanoprost Fixed Combination
Characteristics
Study 1 Study 2
OPC LAT OPC CAR
Na IOP Reduction,b mm Hg Na IOP Reduction,b mm Hg Na IOP Reduction,b mm Hg Na IOP Reduction,b mm Hg
IOP at baseline
>_18 to <21 mm Hg 79 2.7 6 1.7 78 1.7 6 2.0 59 3.3 6 1.7 58 1.5 6 1.7
>_21 to <24 mm Hg 30 3.1 6 2.2 34 1.2 6 2.3 15 3.8 6 2.1 13 1.6 6 2.3
>_24 mm Hg 8 4.5 6 2.9 6 3.7 6 4.9 4 5.8 6 3.4 6 3.0 6 2.2
Diagnosis
POAG 71 3.0 6 2.2 70 1.5 6 2.1 39 3.8 6 2.0 42 1.4 6 1.9
NTG 9 3.7 6 1.7 7 2.0 6 2.1 4 3.5 6 1.0 7 2.3 6 1.3
OH 37 2.5 6 1.7 41 1.7 6 2.7 35 3.1 6 1.9 28 1.9 6 2.0
CAR ¼ carteolol; IOP ¼ intraocular pressure; LAT ¼ latanoprost; NTG ¼ normal tension glaucoma; OH ¼ ocular hypertension; OPC ¼ OPC-
1085EL; POAG ¼ primary open angle glaucoma.
Missing values were imputed using the last-observation-carried-forward method.
aNumber of subjects with both nonmissing baseline values and nonmissing values at each time point.
bMean 6 standard deviation.(Table 8). In the OPC group, 97.4% and 99.2% of patients
reported ‘‘No problems with application at all’’ regarding
the comfort of OPC-1085EL (Table 9) at weeks 4 and 8,
respectively.
Study 2. AEs were observed in 25 of 78 patients (32.1%)
in the OPC group, 12 of 78 patients (15.4%) in the CAR
group, and 8 of 37 patients (21.6%) in the CAR-LAT
group. Of these, ADRs occurred in 15 of 78 patients
(19.2%) in the OPC group, 2 of 78 patients (2.6%) in
the CAR group, and 6 of 37 patients (16.2%) in the
CAR-LAT group (Table 7). One patient with eye pain
discontinued the study in the OPC group, but this AE
resolved without treatment. There were no clinically
significant laboratory abnormalities in any group. There
were no notable differences in vital signs among the 3
groups (Table 8). In the OPC group, 93.5% and 93.6% of
patients reported ‘‘No problems with topical application
at all’’ regarding the comfort of OPC-1085EL (Table 9)
at weeks 4 and 8, respectively.DISCUSSION
THE IOP-LOWERING EFFECT WAS SIGNIFICANTLY GREATER
with OPC than with LAT or CAR, and similar in the
OPC and CAR-LAT groups, at all measured time points.
More patients achieved the target IOPs or target IOP re-
ductions in the OPC group than in the LAT and CAR
groups. The IOP reductions in the OPC group were numer-
ically greater than those in the LAT andCAR groups in the
subgroups of patients with POAG, NTG, or OH. The prev-
alence of NTG is higher in Japanese individuals than inVOL. 171 PHASE 3 TRIALS OF CARTEOLOL/LATother populations25; therefore, the greater IOP reduction
observed with OPC in this population is an important
result. IOP reductions were also observed in the control
groups in both studies. These changes might be owing to
the screening period of 4 weeks being insufficient to reach
a plateau in some patients; alternatively, the reductions
could represent regression to the mean.
A study to investigate the efficacy of the latanoprost/
timolol fixed combination vs latanoprost using a similar
design to Study 1 in Japanese patients with POAG and
OH showed an IOP reduction from baseline in the morning
(8 AM to 11 AM) at week 8 of 2.59 mm Hg with the lata-
noprost/timolol fixed combination and 1.61 mm Hg with
latanoprost—a between-group difference of 0.97 mm
Hg.26 In Study 1, the IOP reduction at predose (9 AM to
11 AM) was 2.9 mm Hg with OPC-1085EL and 1.6 mm
Hg with latanoprost, and the between-group difference
was 1.3 mm Hg. Another study showed that concomitant
therapy with latanoprost and carteolol LA was similar to
latanoprost/timolol fixed combination in terms of the
IOP-lowering effect.27 These results, combined with the
result of Study 2 showing that the IOP-lowering effect of
OPC-1085EL was similar to that of the carteolol/latano-
prost concomitant therapy, suggest that OPC-1085EL is
as effective as the latanoprost/timolol fixed combination.
However, a direct comparison between OPC-1085EL and
the latanoprost/timolol fixed combination may be required
to prove noninferiority of OPC-1085EL.
A prior meta-analysis showed that a fixed combination
of a PG analogue and timolol had weaker IOP-lowering ef-
fects than concomitant therapy.28 These results were
considered to be due to a difference in the daily dose be-
tween fixed-combination therapy and concomitant ther-
apy.20 Noninferiority of a latanoprost/timolol fixed41ANOPROST FIXED COMBINATION
TABLE 5. Number and Percentage of Patients in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination who Achieved the Target
of Intraocular Pressure and Intraocular Pressure Reduction From Baseline at Predose at Week 8
Target value
Study 1 Study 2
OPC (na ¼ 117) LAT (na ¼ 118) Waldde x2 test OPC (na ¼ 78) CAR (na ¼ 77) Waldde x2 test
Nb (%)c Nb (%)c P Value Nb (%)c Nb (%)c P Value
IOP
<_18 mm Hg 88 (75.2) 66 (55.9) .0004 66 (84.6) 45 (58.4) <.0001
<_16 mm Hg 47 (40.2) 27 (22.9) .0038 48 (61.5) 19 (24.7) <.0001
<_14 mm Hg 18 (15.4) 8 (6.8) .0634 14 (17.9) 5 (6.5) .0313
IOP reduction
>_2 mm Hg 89 (76.1) 61 (51.7) .0002 68 (87.2) 39 (50.6) <.0001
>_4 mm Hg 42 (35.9) 25 (21.2) .0201 36 (46.2) 11 (14.3) <.0001
>_6 mm Hg 10 (8.5) 4 (3.4) .2417 13 (16.7) 4 (5.2) .0215
CAR ¼ carteolol; IOP ¼ intraocular pressure; LAT ¼ latanoprost; OPC ¼ OPC-1085EL.
Missing values were imputed using the last-observation-carried-forward method.
aNumber of subjects with both nonmissing baseline values and nonmissing values at each time point.
bNumber of subjects who achieved the target value at week 8.
cPercentage of patients with the target value according to the number of patients with IOP data at week 8.
dLogistic regression model: the response variable was set as the proportion, and the fixed effects were baseline intraocular pressure and
treatment group.
eP values were with treatment group as a fixed effect.
TABLE 6. Mean Intraocular Pressure Reductions in Study 2
of Phase 3 Trials of Carteolol/Latanoprost FixedCombination
Visit Time Point
OPC CAR-LAT
Na
IOP Reduction,b
mm Hg Na
IOP Reduction,b
mm Hg
Week 4 Predose 78 3.1 6 2.0 35 2.7 6 2.1
Week 8 Predose 78 3.5 6 1.9 37 3.1 6 2.3
2 hours 76 2.9 6 1.8 37 2.3 6 2.4
8 hours 62 3.1 6 2.1 30 2.5 6 2.4
CAR ¼ carteolol; CAR-LAT ¼ carteolol/latanoprost concomi-
tant therapy; IOP ¼ intraocular pressure; LAT ¼ latanoprost;
OPC ¼ OPC-1085EL.
Missing values were imputed using the last-observation-
carried-forward method.
aNumber of subjects with both nonmissing baseline values and
nonmissing values at each time point.
bMean 6 standard deviation.combination to concomitant therapy with latanoprost QD
plus timolol BID was not confirmed.29 Although a travo-
prost/timolol fixed combination was noninferior to travo-
prost QD plus timolol QD,30 the effect was not assessed
by comparison to a standard daily dose of concomitant
therapy (ie, travoprost QD plus timolol BID). In addition,
in a study comparing BID application of a dorzolamide/
timolol fixed combination and a concomitant therapy
with dorzolamide 3-times-daily plus timolol BID, the42 AMERICAN JOURNAL OFIOP-lowering effect was similar between the 2 treatments
at 2 hours after application, but the percent reduction
from baseline was lower at 0 and 8 hours after application
in the fixed combination group than in the concomitant
therapy group.31 The daily dose of the active ingredients
of OPC-1085EL is the same as that in concomitant therapy
with carteolol LA and latanoprost. A pharmacokinetic
study in rabbits confirmed that the concentrations of
each active ingredient of OPC-1085EL in the aqueous hu-
mor and iris/ciliary body are not lower than carteolol LA or
latanoprost (unpublished data: ClinicalTrials.gov
NCT02108288). In Study 2, OPC-1085EL displayed
similar efficacy to concomitant therapy with carteolol LA
and latanoprost. Therefore, we believe that switching
from concomitant therapy to OPC-1085EL may improve
convenience for patients while maintaining the IOP-
lowering effects.
In the present studies, the ophthalmic drugs were applied
in the morning. Because studies of beta blocker/PG
analogue fixed-combination drugs have reported better
IOP reduction with evening than with morning applica-
tion,32,33 OPC-1085EL may exert greater IOP-lowering ef-
fects when applied in the evening. It may be necessary to
further investigate the relationship between the time of
application and the IOP-lowering effect.
No new safety concerns, other than known ADRs for
each single agent, were identified in the OPC group in
either of our studies. All ADRs, including the ADRs that
led to study discontinuation in 1 patient, were rated as
mild in severity. Although the incidence of ADRs inNOVEMBER 2016OPHTHALMOLOGY
TABLE 7. Adverse Drug Reactions in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Study 1 Study 2
OPC (N ¼ 118) LAT (N ¼ 119) OPC (N ¼ 78) CAR (N ¼ 78) CAR-LAT (N ¼ 37)
N (%) N (%) N (%) N (%) N (%)
Patients with adverse drug reactions 8 (6.8) 5 (4.2) 15 (19.2) 2 (2.6) 6 (16.2)
Ocular events
Growth of eyelashes 2 (1.7) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Blepharal pigmentation 0 (0.0) 2 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
Vision blurred 2 (1.7) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Eye pruritus 1 (0.8) 1 (0.8) 2 (2.6) 0 (0.0) 0 (0.0)
Erythema of eyelid 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 1 (2.7)
Eye discharge 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Eye irritation 0 (0.0) 1 (0.8) 2 (2.6) 0 (0.0) 1 (2.7)
Punctate keratitis 1 (0.8) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Visual impairment 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Foreign body sensation in eyes 1 (0.8) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
Conjunctival hyperemia 0 (0.0) 1 (0.8) 2 (2.6) 1 (1.3) 2 (5.4)
Ciliary hyperemia 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Eye pain 0 (0.0) 0 (0.0) 3 (3.8) 0 (0.0) 0 (0.0)
Ocular hyperemia 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 1 (2.7)
Abnormal sensation in eye 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
Blepharitis 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
Corneal disorder 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 1 (2.7)
Conjunctivitis allergic 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Instillation site irritation 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypertrichosis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.7)
Nonocular events
Dysgeusia 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0)
Diarrhea 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
CAR ¼ carteolol; CAR-LAT ¼ carteolol/latanoprost concomitant therapy; LAT ¼ latanoprost; OPC ¼ OPC-1085EL.
Adverse events were coded using the Medical Dictionary for Regulatory Activities, version 17.0.
All events were mild in severity.Study 2 was higher in the OPC group than in the CAR
group, all of the ADRs in the OPC group were rated as
mild in intensity and were tolerable. The incidence was
similar to that in the CAR-LAT group, and there were
no AEs with an unexpectedly high incidence.
Major eye disorders reported to be specific to PG ana-
logues include ‘‘conjunctival hyperemia,’’ ‘‘blepharal
pigmentation,’’ and ‘‘keratitis punctuate.’’ In our studies,
the incidence of ‘‘conjunctival hyperemia’’ was lower
than was previously reported for latanoprost,34 and other
specific disorders (eg, blepharal pigmentation, iris pigmen-
tation, hypertrichosis of eyelid, and prostaglandin-
associated periorbitopathy) were not reported in the OPC
group. The lower incidence of these eye disorders may be
attributable to the short observation period. Our results
suggest no significant safety concerns based on the class ef-
fects associated with PG analogues, but this should be
confirmed in long-term observation.
Beta blockers can affect the cardiovascular system.
Although carteolol may affect the cardiovascular system,
its effects are weaker than those of timolol.9 In the presentVOL. 171 PHASE 3 TRIALS OF CARTEOLOL/LATstudies, no cardiovascular ADRs were reported in the
OPC, CAR, or CAR-LAT groups. In Study 2, changes in
the pulse rate and blood pressure in the OPC group were
similar to those observed in the CAR and CAR-LAT
groups. These results are consistent with those of an OPC-
1085EL pharmacokinetic study, in which the PK parameters
of human plasma carteolol after application ofOPC-1085EL
were similar to those after application of carteolol LA
(ClinicalTrials.gov NCT02108288). In each treatment
group in Study 2, the pulse rate at week 8 tended to be lower
than those observed at baseline and at week 4. This may be
attributable to a transient increase in the blood drug con-
centration immediately after application in association
with different measurement time points (predose at baseline
and week 4, and at 2 hours after dosing at week 8).
Regarding ADRs that may affect treatment adherence, a
previous study comparing latanoprost/timolol fixed combi-
nation and latanoprost26 reported a higher incidence of
‘‘eye irritation’’ in the latanoprost/timolol group (16.7%)
than in the latanoprost group (0.7%). In our studies,
OPC-1085EL caused ‘‘eye irritation’’ and ‘‘eye pain,’’ but43ANOPROST FIXED COMBINATION
TABLE 8. Changes in Patient Vital Signs in Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Parameters Visit
Study 1 Study 2
OPC LAT OPC CAR CAR-LAT
Na Mean 6 SD Na Mean 6 SD Na Mean 6 SD Na Mean 6 SD Na Mean 6 SD
Pulse rate, beats/min Baselineb 118 75.0 6 11.8 119 77.4 6 11.5 78 71.0 6 10.5 78 71.4 6 10.8 37 75.2 6 9.5
Week 4c 115 70.7 6 9.5 117 77.5 6 10.4 77 72.0 6 10.4 78 72.0 6 10.3 35 74.6 6 9.9
Week 8d 117 68.9 6 9.0 119 75.2 6 11.4 78 68.2 6 8.6 77 70.1 6 9.4 37 70.8 6 9.6
Systolic blood pressure, mm Hg Baselineb 118 132.2 6 17.5 119 132.2 6 20.4 78 128.6 6 18.6 78 128.2 6 18.6 37 126.0 6 19.2
Week 4c 115 129.2 6 16.4 117 132.6 6 17.4 77 127.5 6 18.3 78 126.7 6 16.5 35 127.5 6 20.3
Week 8d 117 128.0 6 17.4 119 132.3 6 16.9 78 127.2 6 19.1 77 126.0 6 17.7 37 125.1 6 20.2
Diastolic blood pressure, mm Hg Baselineb 118 80.3 6 11.3 119 79.5 6 11.7 78 76.7 6 12.0 78 77.5 6 12.4 37 76.2 6 12.3
Week 4c 115 78.9 6 10.9 117 80.4 6 11.7 77 76.0 6 11.2 78 77.3 6 10.5 35 77.0 6 13.5
Week 8d 117 77.8 6 11.3 119 80.5 6 11.1 78 75.6 6 10.7 77 77.3 6 11.6 37 74.7 6 11.6
CAR ¼ carteolol; CAR-LAT ¼ carteolol/latanoprost concomitant therapy; LAT ¼ latanoprost; OPC ¼ OPC-1085EL.
aNumber of subjects with nonmissing values at each time point.
bPredose at the end of screening.
cPredose at week 4.
dTwo hours after dosing at week 8 or at discontinuation.
TABLE 9. Comfort Scores at Weeks 4 and 8 of Phase 3 Trials of Carteolol/Latanoprost Fixed Combination
Visit Comfort Scorea
Study 1 Study 2
OPC LAT OPC CAR CAR-LAT
N (%)b N (%)b N (%)b N (%)b N (%)b
Week 4c 0 112 (97.4) 112 (95.7) 72 (93.5) 75 (96.2) 29 (82.9)
1 3 (2.6) 4 (3.4) 3 (3.9) 3 (3.8) 6 (17.1)
2 0 (0.0) 1 (0.9) 1 (1.3) 0 (0.0) 0 (0.0)
3 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0)
Week 8d 0 117 (99.2) 116 (97.5) 73 (93.6) 74 (94.9) 33 (89.2)
1 0 (0.0) 3 (2.5) 3 (3.8) 4 (5.1) 4 (10.8)
2 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
3 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
CAR ¼ carteolol; CAR-LAT ¼ carteolol/latanoprost concomitant therapy; LAT ¼ latanoprost; OPC ¼ OPC-1085EL.
a0: ‘‘No problems with application at all’’; 1: ‘‘Some trouble with application, but no problems’’; 2: ‘‘Trouble with application, but bearable’’;
and 3: ‘‘Unbearable trouble with application.’’
bPercentages calculated vs number of subjects with measured comfort of study drug values at each visit.
cPredose at week 4.
dTwo hours after dosing at week 8 or at discontinuation.all events were mild and infrequent. Regarding the comfort
in the use of the study drug, most of the patients answered
‘‘No problems with application.’’
We consider that the incidence of corneal disorders was
lower in the OPC group than in other groups in these
studies because OPC-1085EL does not contain benzalko-
nium chloride.7,35 However, it was not possible to
compare the results because of the low incidence of these
events; only 1 patient experienced corneal epithelium
disorder, which is coded as ‘‘corneal disorder’’ in44 AMERICAN JOURNAL OFMedDRA, in each of the OPC and CAR-LAT groups in
Study 2.
Taken together, these findings suggest that OPC-1085EL
poses no greater safety risks than, and is tolerated as well as,
latanoprost, carteolol, and their concomitant therapy.
These studies have some limitations. In both, the IOP-
lowering effect was investigated only after morning appli-
cation. Further studies are needed to assess the effect of
OPC-1085EL applied at other times. Second, the treat-
ment duration was short, and the efficacy and safety ofNOVEMBER 2016OPHTHALMOLOGY
long-term treatment need to be further investigated. Third,
both studies only enrolled Japanese patients.
In conclusion, in patients with POAG and OH, OPC-
1085EL achieved a significantly greater IOP-lowering ef-
fect than latanoprost and carteolol and had comparable
effects to carteolol/latanoprost concomitant therapy.VOL. 171 PHASE 3 TRIALS OF CARTEOLOL/LATOPC-1085EL posed no new safety concerns. These results
indicate that OPC-1085EL is a useful IOP-lowering treat-
ment in patients who respond poorly to monotherapy.
Switching to OPC-1085EL from concomitant therapy
may improve convenience for patients while maintaining
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